Cliff Belliveau and Phil Walls Featured in R&I Insights Email

The COVID-19 pandemic will continue to have an impact on workers’ compensation pharmacy for the foreseeable future. Recently, myMatrixx Vice President of Business Intelligence, Cliff Belliveau, joined Chief Clinical Officer, Phil Walls, to discuss this new landscape for industry publication Risk & Insurance’s Insights feature.
Learn more

New York Drug Formulary Notice of Delay

On May 24, 2021, the New York Workers’ Compensation Board (WCB) Chair delayed the implementation of amendments to the following regulations, which were scheduled to become effective on June 7, 2021...
Learn more
Doctor and patient

New Clinically Speaking Video Discusses COVID-19 Long-Haulers

“Long-haulers” are individuals who have been infected by COVID-19 and have recovered from the acute infection, but continue to have lingering symptoms. It’s important to monitor these patients as there’s emerging evidence of ongoing morbidity or chronic suffering from COVID-19.
Learn more
Healthcare cure concept with a hand in blue medical gloves holding Coronavirus, Covid 19 virus, vaccine vial

Update to Search for Safe and Effective COVID-19 Vaccines Document

One of the top priorities for successfully mitigating COVID-19 is the development of an effective yet safe vaccine. Currently there are more than 100 potential vaccines in development, with projections for commercial availability a year or more away. To provide the latest information, myMatrixx is...
Learn more

Cigna Launches New Health Services Brand Evernorth

On September 16th, myMatrixx parent company Cigna announced the launch of a new brand for its growing portfolio of high-performing health services. Evernorth was created to accelerate delivery of flexible solutions to meet the diverse needs of health plans, employers and government organizations....
Learn more
Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.

Qdolo FDA Approved

Qdolo ™ (tramadol – Athena Bioscience) oral solution, 5mg/mL was approved on Sept. 1, 2020, by the U.S. Food and Drug Administration (FDA). A C-IV controlled substance, it is indicated for treating adults who have severe pain that requires an opioid, but that does not respond to other treatments....
Learn more

myMatrixx Names David Dubrof as Chief Sales Officer

myMatrixx, an Express Scripts Company today announced that David Dubrof has been named Chief Sales Officer for the organization. “We’re absolutely thrilled to have David join our team,” said Mike Cirillo, President of myMatrixx. “His 25-plus years of executive management experience in sales,...
Learn more

Phil Walls Quoted in Risk & Insurance on Medical Marijuana

Medical marijuana use continues to be a topic of debate in the workers’ compensation space, with states reviewing its legality and industry professionals trying to better understand its utility as a treatment. Recently, myMatrixx Chief Clinical Officer, Phil Walls, was quoted in an article for ...
Learn more
Coronavirus prevention medical surgical masks and hand sanitizer gel for hand hygiene corona virus protection.

MedWatch Update on Hand Sanitizers

During June and July, the FDA has issued a series of warnings that some commercial hand sanitizers contain methanol and it has asked a number of manufacturers to recall their products. Also known as wood alcohol, methanol is intended for industrial use in products such as pesticides and solvents....
Learn more
Vial of naloxone with syringe

MedWatch Update on Naloxone

In a Safety Communication on July 23, 2020, the FDA alerted prescribers, pharmacies and patients of a new requirement for opioid drugs. It is directing drug companies that make opioids for pain relief and for use in treating opioid use disorder to add information on the labels about the use of naloxone....
Learn more
Doctor holding Dexamethasone steroid drug

Update on Dexamethasone Use for COVID-19 Treatment

Preliminary results from a randomized, controlled, open-label, adaptive study on the use of dexamethasone were added to myMatrixx’s “Coronavirus Disease 2019 (COVID-19) – The Search for a Treatment” document. The recovery trial compared a ten day course of dexamethasone 6mg once per day versus...
Learn more
3d modern office interior render

Resources for Returning to the Worksite

With government agencies and workplace organizations establishing guidelines for businesses to safely return employees to worksites, myMatrixx will be following the recommendations recently given by our parent company Express Scripts . On the overview page, which can be found here , there are guides...
Learn more

Information and Guidelines for Novel Coronavirus (COVID-19)

myMatrixx is closely monitoring the 2019 Novel Coronavirus (COVID-19) and our top priority is the safety and service of our customers, clients, employees and partners. “The spread of the novel coronavirus, COVID-19, is raising concerns around the world. People want to know how to stay safe, how...
Learn more

FDA Update on COVID-19 Treatment

Today, the FDA revoked the Emergency Use Authorization (EUA) which allowed for chloroquine and hydroxychloroquine donated to the Strategic National Stockpile (SNS) to be distributed and used to treat certain hospitalized patients with COVID-19 when a clinical trial was unavailable, or participation...
Learn more
Phil Walls_website_800x800

Webinar on Settling Legacy Claims to Feature Phil Walls

myMatrixx Chief Clinical Officer, Phil Walls, will join Dan Anders, Esq., Chief Compliance Officer for Tower MSA Partners on Wednesday, May 20, 2020, from 2:00 PM to 3:00 PM EDT as panelists in a webinar discussing effective solutions for settling legacy workers’ compensation claims. It’s well...
Learn more
Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.

MedWatch Update: Warning Issued on COVID-19 Drugs

The FDA has issued a warning against the use of hydroxychloroquine and chloroquine for COVID-19 outside a hospital or clinical trial setting due to the increased risk for heart rhythm issues. These medications have not been shown to be safe and effective for treating or preventing COVID-19. Earlier...
Learn more
White Paper Thumbnail For Website

myMatrixx Releases New Report on the Impact of an Aging Workforce

With an aging population that is increasingly choosing to stay in the workforce past the standard retirement age, new issues are emerging in the field of workers’ compensation and workplace medical management. In light of these trends, myMatrixx has published a report on this topic, titled “Preparing...
Learn more
Brand to Generic Guide_thumbnail

2020 Updates for Drug Reference Guides

Our “Workers’ Compensation Pharmaceuticals: Prior Authorization and High Dollar Rejections Guide” and our “Brand to Generic Reference Guide: Workers’ Compensation Pharmaceuticals” are two of the most widely used reference materials at myMatrixx. Due to the constantly changing nature...
Learn more

myMatrixx Leaders to Present at Upcoming RIMS Chapter Events

In a recent update , we shared that myMatrixx Clinical Account Executive Shanea McKinney has had multiple speaking proposals accepted to RIMS, the risk management society’s Professional Exchange of Risk Knowledge, or PERK, program. Well, we’re pleased to announce that two separate RIMS chapters...
Learn more
CEU Institute final cs

myMatrixx Leaders to Present at CEU Institute Courses

Over the coming months, members of the myMatrixx clinical team will be delivering educational presentations for the CEU Institute, a national continuing education accreditation management organization. myMatrixx Chief Clinical Officer Phil Walls and Clinical Account Executive Shanea McKinney will...
Learn more

myMatrixx Rated Best In Class Among PBMs

Recently, CompPharma, an industry-leading consulting service that provides valuable insights to both payers and PBMs, released its 2019 Prescription Drug Management in Workers’ Compensation Survey Report. The report collected survey responses from 31 respondents, including clinical personnel and...
Learn more
Phil Walls Headshot with Updated Background

myMatrixx Experts Talk WC Drug Spend with

Speaking in a recent profile with industry news website, myMatrixx Chief Clinical Officer Phil Walls again shared his thoughts on rising drug costs and how to manage them. Walls is quoted as saying that while extreme price hikes grab headlines, and are an important factor,...
Learn more
Untitled design (1)

Phil Walls and Cliff Belliveau to Present at 2019 NWCDC

The myMatrixx team is excited to be attending and exhibiting at this year’s National Workers’ Compensation and Disability Conference , which will be held November 6-8 in Las Vegas, Nevada.  A key part of our presence at the event will be speaking engagements from Chief Clinical Officer, Phil...
Learn more

myMatrixx Adds New Clinical Account Executive To Pharmacy Team

myMatrixx has added a new Clinical Account Executive to their team, Shanea McKinney, PharmD . Prior to joining myMatrixx, Shanea served as Director Client Services, Managed Care for Sedgwick . In her role, Shanea worked with Sedgwick Program Managers and key clients to provide analytical support...
Learn more
Mike Cirillo Headshot

More Insights from myMatrixx President on Cost Transparency

Picking up where he left off last week, myMatrixx President, Mike Cirillo, took a deeper dive into pharmacy benefits management pricing models in the second part of his “Leaders Speak” feature. In the Work Comp Wire article, Cirillo breaks down the difference between spread pricing models and...
Learn more
Mike Cirillo Headshot

Mike Cirillo Talks Cost Transparency with Work Comp Wire

myMatrixx President, Mike Cirillo, shared his thoughts and insights on the topic of value in pharmacy management in a recent profile with industry news site, Work Comp Wire. The article is part of the publication’s recurring “Leaders Speak” series, giving a forum for industry leaders to share...
Learn more

Phil Walls Quoted in Article for Work Comp Central

In response to ongoing efforts to fight the opioid crisis, drug companies are working to bring non-addictive opioid pain medication to market. With the FDA’s announcement to postpone the decision to approve a new type of this drug, loxicodegol, Work Comp Central Magazine reached out to myMatrixx...
Learn more
Sarah Wasselle

myMatrixx Business Intelligence Team Adds New Developer

myMatrixx has added Sarah Wasselle to their Business Intelligence team, joining as a Senior Business Systems Analyst and Developer. Sarah graduated from the University of Florida with a degree in Industrial Engineering and is currently pursuing a master's from the University of South Florida in...
Learn more

myMatrixx launches myPassport®SM at the 2019 WCI Conference

The myMatrixx team will be attending the 2019 Workers’ Compensation Institute Conference in August, where we’re excited to launch myPassport®, our new pharmacy benefits management (PBM) tool. myPassport represents a new industry standard in PBM for workers’ compensation claims and was created...
Learn more

myMatrixx Leadership Team Quoted In Drug Trends Article

Overall opioid use is declining and the prescribing of these drugs is starting to get under control, however, there are a few new trends that may hamper this progress. Some members of our leadership team weighed in on these evolving trends in a recent Risk & Insurance  article.
Learn more

myMatrixx names Jason Gagliano Vice President of National Sales

myMatrixx is pleased to announce that Jason Gagliano has been named Vice President of National Sales. Gagliano, who has over 20 years of experience in managed care, is committed to building lasting partnerships with clients and developing new relationships to drive growth. His previous work with...
Learn more

VP Kim Ehrlich Elected to AAPAN Board

myMatrixx is proud to announce that Kim Ehrlich , Vice President of Regulatory Compliance, was recently elected to the American Association of Payers, Administrators and Networks (AAPAN) board. Kim has been involved in the industry for over 25 years. Thanks to her former experience as a claims...
Learn more